Zai Lab (MEX:ZLAB N) YoY EBITDA Growth: 13.57% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ZLAB N Zai Lab Ltd MEX:ZLAB N
64 GF Score
Price MXN810.00
GF Value MXN1,269.49
! 7 Warning Signs
View Full Analysis

What is Zai Lab YoY EBITDA Growth?

Zai Lab MEX:ZLAB N 64 YoY EBITDA Growth is 13.57% as of Mar. 2026. GuruFocus rates MEX:ZLAB N with a GF Score™ of 64/100 and a GF Value™ of MXN1,269.49. The stock has 7 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Zai Lab's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 13.57%.

Zai Lab's EBITDA per Share for the three months ended in Mar. 2026 was MXN-7.16.

Zai Lab YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Zai Lab's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab YoY EBITDA Growth Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -125.83 41.82 35.37 10.44 49.21

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.46 57.29 33.13 50.45 13.57
MEX:ZLAB N
64GF Score
Zai Lab Ltd MEX:ZLAB N
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Zai Lab's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-26.014--51.217)/ | -51.217 |
=49.21 %

Zai Lab's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-7.164--8.289)/ | -8.289 |
=13.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 13.57% mean?
Zai Lab (MEX:ZLAB N) has a YoY EBITDA Growth of 13.57% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Zai Lab and its competitors.
Is Zai Lab's YoY EBITDA Growth too high?
Zai Lab's current YoY EBITDA Growth is 13.57%. Overall, Zai Lab has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's YoY EBITDA Growth compare to STOK and ADMA?
Zai Lab's YoY EBITDA Growth of 13.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Zai Lab and its competitors. Zai Lab's current YoY EBITDA Growth is 13.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Zai Lab (MEX:ZLAB N) has a current YoY EBITDA Growth of 13.57%. The stock's GF Value™ is MXN1,269.49, compared to a current price of MXN810.00 — trading 36.2% below its estimated fair value. The current YoY EBITDA Growth is 13.57%. Zai Lab's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Zai Lab (MEX:ZLAB N), the current YoY EBITDA Growth is 13.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (MEX:ZLAB N) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of MXN810.00 is trading 36.2% below its estimated GF Value™ of MXN1,269.49.

Key valuation signals for MEX:ZLAB N:

  • YoY EBITDA Growth: 13.57%
  • GF Value™: MXN1,269.49 vs. price of MXN810.00 (36.2% below fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the MEX:ZLAB N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for MEX:ZLAB N

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN1,269.49
GF Value